|

Accuracy of Indocyanine Green (ICG) Fluorescence Imaging in Giant Cell Tumor of Bone Surgery

RECRUITINGPhase 4Sponsored by Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Actively Recruiting
PhasePhase 4
SponsorShanghai Jiao Tong University Affiliated Sixth People's Hospital
Started2026-01-02
Est. completion2026-12
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted

Summary

This study evaluates the diagnostic accuracy of Indocyanine Green (ICG) fluorescence imaging in visualizing residual lesions of Giant Cell Tumor of Bone (GCTB) in the tumor cavity during surgery. Patients diagnosed with GCTB will receive an intravenous injection of ICG prior to the operation to label tumor tissues. During the procedure, surgeons will use a near-infrared fluorescence imaging system to visualize the tumor cavity and identify potential residual lesions after standard curettage. The study aims to determine the sensitivity, specificity, positive predictive value, and negative predictive value of ICG fluorescence imaging by comparing the intraoperative fluorescence findings with the final pathological results of the validation samples.

Eligibility

Age: 18 Years – 75 YearsHealthy volunteers accepted
Inclusion Criteria:

* Diagnosed with Giant Cell Tumor of Bone(GCTB), via preoperative biopsy or typical imaging (MRI), and scheduled for surgical resection.
* Capable of understanding the study and voluntarily signing the written informed consent form.

Exclusion Criteria:

* Known severe history of allergy to Indocyanine Green (ICG) or iodine.
* Severe liver dysfunction.
* Women who are pregnant or lactating.

Conditions2

CancerGiant Cell Tumor of Bone

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.